(0.20%) 5 557.25 points
(-0.04%) 39 536 points
(0.34%) 20 109 points
(0.66%) $82.28
(0.93%) $2.71
(0.01%) $2 336.90
(1.79%) $29.44
(1.95%) $1 011.00
(0.16%) $0.935
(0.43%) $10.67
(0.05%) $0.791
(1.74%) $86.48
0.59% HKD 25.45
Live Chart Being Loaded With Signals
Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China...
Stats | |
---|---|
Dzisiejszy wolumen | 695 980 |
Średni wolumen | 1.56M |
Kapitalizacja rynkowa | 8.01B |
EPS | HKD-1.800 ( Q4 | 2023-12-31 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E |
-7.21 (Sector) 0 (Industry) 0 |
ATR14 | HKD0.0460 (0.18%) |
Wolumen Korelacja
Ascentage Pharma Group Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Ascentage Pharma Group Korelacja - Waluta/Towar
Ascentage Pharma Group Finanse
Annual | 2023 |
Przychody: | HKD221.98M |
Zysk brutto: | HKD191.44M (86.24 %) |
EPS: | HKD-3.37 |
FY | 2023 |
Przychody: | HKD221.98M |
Zysk brutto: | HKD191.44M (86.24 %) |
EPS: | HKD-3.37 |
FY | 2022 |
Przychody: | HKD209.71M |
Zysk brutto: | HKD187.71M (89.51 %) |
EPS: | HKD-3.35 |
FY | 2021 |
Przychody: | HKD27.91M |
Zysk brutto: | HKD24.58M (88.08 %) |
EPS: | HKD-3.07 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Ascentage Pharma Group
Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation, as well as for patients with tyrosine kinase inhibitor resistant chronic phase chronic myeloid leukemia. It also has APG-2575, an orally administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors, which is under Phase Ib/II clinical study; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interaction for treating solid tumors and hematological malignancies; and APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection. In addition, it is involved in the development of APG-1252, a small molecule drug to restore apoptosis through selective inhibition of the Bcl-2 and Bcl-xL proteins for SCLC, lymphoma, and other solid tumors; APG-2449 for non-small-cell lung carcinoma; APG-5918, an orally available and selective EED inhibitor with a best-in-class potential that is under pre-clinical stage; APG-265, which is in the IND-enabling stage for hematological malignancies and solid tumors; and UBX1967/1325 targeting Bcl family indicated for DME that is under Phase II development. Ascentage Pharma Group International has collaboration relationships with major biotechnology and pharmaceutical companies, and academic institutions, which include Innovent Biologics, Inc.; National Cancer Institute; Pfizer Inc.; and Clover Biopharmaceuticals (Hong Kong) Co., Limited. The company was founded in 2009 and is headquartered in Suzhou, China.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej